Small Cap Feast
Small Cap Feast – 21 July 2020
Dish of the Day:
No Joiners Today
No Joiners Today
Off the Menu:
No Leavers Today
No Leavers Today
What’s Cooking in the IPO Kitchen?
AEX Gold (TSXV:AEV) is intending to admit its shares to AIM alongside a £45m placing. The Company, led by CEO Eldur Ólafsson, has established the largest land package of gold assets in Greenland with a current portfolio of licences covering 3,356 square kilometres, in the two known gold belts in Southern Greenland, the Nanortalik and Tartoq gold belts. Nalunaq is a high-grade gold asset with an updated Inferred Mineral Resource covering 422,770 tonnes at 18.5 grams per tonne of gold, or 250,970 ounces of gold, which covers the area in and around the historical mine. Due July. Current mkt cap C$66.7m.
Deltic Energy 0.85p £12m (DELT.L)
On 15 July 2020, Reabold Resources plc announced a potential all share offer for the issued and to be issued share capital of Deltic Energy .
After consideration of the Proposed Offer with its advisers, on 16 July 2020, Deltic Energy announced that its board had rejected the Proposed Offer.
Deltic today announced that on 20 July 2020 it received a letter from IPGL (Holdings) Limited (“IPGL”), a company controlled by Michael Spencer, and the largest shareholder in Deltic. In this letter, , IPGL stated its intention not to support the Proposed Offer and reiterated its continuing support of Deltic’s management team, its technical capability, focused asset base with high impact potential and current strategy.
KRM 22 28 £7.5m (KRM.L)
The technology and software investment company that focuses on risk management for capital markets, today issues a trading update for the 6 months to 30 June 2020 .
The first half has been impacted by the effects of COVID-19 but progress has been made with two new customer wins and cost and debt reduction in the Period.
As described in the trading update of 2 April 2020, the Company has experienced slowed business activity and extended sales cycles as customers and prospects have transitioned to home working and with the increased operational burden resulting from market volatility. Notwithstanding the backdrop, the Company has secured two new customers in the period and sold additional products to an existing customer adding an aggregate of £0.3m in ARR in the period resulting in a total ARR as at 30 June 2020 of £4.0m (which excludes a disputed contract with ARR of £0.3m). The new contracts include the purchase of Enterprise and Market Risk products.
REACT Group 1.25p £6.2m (REAT.L)
The specialist cleaning, hygiene and decontamination company, is delighted to announce it has been awarded a number of contracts from one of its large Facilities Management (“FM”) customers to provide specialist deep cleaning services to a number of sites across the United Kingdom.
The batch of twelve contracts, worth just over £350k will run for a period of five weeks through to the end of the August 2020. They each require experience and specialist skills core to the REACT business, including safe working practices at height and in potentially hazardous environments.
These contracts are incremental to the work REACT carries out for this customer and is non-COVID-19 related.
SDI Group 59p £57.5m (SDI.L)
The Group focused on the design and manufacture of scientific and technology products for use in digital imaging and sensing and control applications, announced its final audited results for the year ended 30 April 2020.
- Revenue increased 41% to £24.5m (2019: £17.4m) · Revenue growth both organic (4%) and from acquisitions (36%), reflecting full year contributions from Fistreem International, Thermal Exchange, Graticules Optics and MPB Industries
- Adjusted operating profit increased 48% to £4.6m (2019: £3.1m)
o Reported operating profit increased 60% to £3.5m (2019: £2.2m)
- Adjusted profit before tax increased 44% to £4.3m (2019: £3.0m)
o Reported profit before tax increased 54% to £3.3m (2019: £2.1m)
- Adjusted diluted EPS increased 23% to 3.43p (2019: 2.83p)
SDI Group has started the current year in a strong financial position and a number of our companies have seen increased demand for medical products which are being used to address the COVID-19 challenges. Other companies within the Group face some uncertainty and a downturn in orders although all our manufacturing facilities remain in operation. There are early signs of a return to normality in trading and overall SDI remains profitable and cash generative. SDI continues to seek acquisitions and looks forward to growing organically and through acquisition as conditions improve.
Conroy Gold 23.5p £6.2m (CGNR.L)
- Heads of Terms signed for proposed Joint Venture with Anglo Asian Mining
- The Joint Venture goal is the development of a gold mine and further exploration and development along the district scale gold trend which the Company has discovered in Ireland
- Anglo Asian Mining to acquire an i initial 17.5% working interest in the Joint Venture for committing to spend €2 million on a primary expenditure programme
- Option to increase working interest to 25% by spending a further €2 million to complete the Primary Expenditure Programme of a minimum of €4 million
- Further option to acquire a total 55% working interest in exchange for committing to meet the expenditures of the Secondary Expenditure Programme in order to advance the Clontibret Gold Deposit to mine construction ready status and certain further exploration expenditures
- 325,000 Warrants to acquire ordinary shares in Conroy Gold at 16p issued to Anglo Asian with further warrants proposed to be issued upon completion of the final Joint Venture Agreement
Thor Mining 0.37p £4.7m (THR.L)
High grade uranium and vanadium assay results from Colorado mineral claims held by American Vanadium Pty Ltd (AVU). AVU holds interests in uranium and vanadium focussed projects in Colorado and Utah in the United States of America. The Company announced on 1 June 2020 an option agreement to acquire AVU, subject to satisfaction of due diligence requirements. These final high-grade uranium assays are from 13 outstanding samples deemed too radioactive for the original laboratory.
- The 13 assay results averaged 0.706% U3O8 and 1.36% V2O5.
- Four samples assayed 1.0% U3O8 or greater with a best uranium assay of 1.25%U3O8
- Three samples assayed over 2%V2O5 with a best vanadium assay of 3.47% V2O5
- Samples previously tested and reported were also assayed in the Hazen laboratory with results slightly above, but broadly confirming the earlier report.
Frontier IP 59p £30m (FIPP.L)
Further to the announcements made yesterday, FIPP announced the successful completion of the Capital Raising at an Issue Price of 55 pence per share.
The Placing and PrimaryBid Offer were comfortably oversubscribed and, as a result, in aggregate comprise of the maximum available number of 4,243,140 New Ordinary Shares, raising gross proceeds of approximately £2.33 million for the Company. The Issue Price represents a 14.1 per cent. discount to the closing middle market price of 64 pence on 17 July 2020,Net proceeds of the Capital Raising to:
o support the ongoing working capital needs of the business, including to increase headcount to increase Frontier’s capacity to provide commercialisation and development services for its portfolio companies; and
o flex the Company’s business model to include both bridge funding and direct participation in investment rounds for portfolio companies.
Minoan Group 1.2p £5.25m (MIN.L)
Minoan announced the successful reorganisation of its only secured borrowings , the cancellation of warrants and rights to future warrants and a small pre funded placing to provide further working capital.
Whilst the transaction is complicated and involves short term cost it will result in a significant reduction in the long term fully diluted capital for the benefit of all shareholders.
The Company has also announced today that it is proposing to raise approximately £200,000 through the issue of new Ordinary Shares at a price of 1.1 pence per share. The Chairman, Christopher Egleton and two directors of subsidiary company Loyalward Limited, being David Raby and Nicholas Day, have indicated their intention to participate in this placing.
Ergomed 585p £283m (ERGO.L)
The company focused on providing specialised services to the pharmaceutical industry, today announces a trading update for the first half of 2020.
EBITDA for FY 2020 expected to be materially ahead of market expectations
- Integrated pharmaceutical services business demonstrates resilience during Covid-19
- Total revenue growth of 14.8% over H1 2019; like for like service fee revenue up 18.0% over H1 2019
- Order book up 22.0% since 1 January 2020 provides high visibility into H2 2020 and beyond
- Strong cash balance of £14.1 million and debt free
0203 764 2344
*A corporate client of Hybridan LLP
This document, which does not constitute research, has been issued by Hybridan LLP for information purposes only and should not be construed in any circumstances as an offer to sell or solicitation of any offer to buy any security or other financial instrument, nor shall it, or the fact of its distribution, form the basis of, or be relied upon in connection with, any contract relating to any such action. This document has no regard for the specific investment objectives, financial situation or needs of any specific person or entity and is not a personal recommendation to any such person or entity. Recipients should reach an individual investment decision, based upon their respective financial objectives and financial resources and, if any doubt, should seek advice from an investment advisor.
The information contained in this document is based on materials and sources that are believed to be reliable; however, such information has not been independently verified and therefore it is not possible to confirm such information as being accurate. This document is not intended to be a complete statement or summary of any securities, markets, reports or developments referred to herein. No representation or warranty, either express or implied, is made or accepted by Hybridan LLP, its members, officers, employees, agents or associated undertakings in relation to the accuracy, completeness or reliability of the information contained in this document, nor should it be relied upon as such.
The content of this document includes market commentary and other information which we have prepared in relation to the company referred to in this document, which is our broking client. The provision of this document to you constitutes a minor non-monetary benefit which is capable of enhancing the quality of service provided by Hybridan LLP and which is of a scale and nature which could not be judged to impair the duty of Hybridan LLP to act in the best interest of its client falling within article 24(7)(b) of Regulation 600/2014/EU (MIFID II Regulation).
Any and all opinions expressed are current as of the date appearing on this face of this document only. Any and all opinions expressed are subject to change without notice and Hybridan LLP is under no obligation to update the information contained herein. To the fullest extent permitted by law, none of Hybridan LLP, its members, officers, employees, agents or associated undertakings shall have any liability whatsoever for any direct or indirect or consequential loss or damage (including lost profits) arising in any way from use of all or any part of the information in this document.
This document should not be relied upon as being an independent or impartial view of the subject matter and, for the avoidance of doubt, constitutes non-independent research (as such term is defined in the Financial Conduct Authority’s Conduct of Business Sourcebook to reflect the requirements of the MIFID II Regulation and Directive 2014/65/EU (known as MIFID II)). The individuals who prepared this document may be interested in shares in the company concerned and/or other companies within its sector, may be involved in providing other financial services to the company or companies referenced in this document or to other companies who might be said to be competitors of the company or companies referenced in this document. As a result both Hybridan LLP and the individual members, officers and/or employees who prepared this document may have responsibilities that conflict with the interests of the persons who receive this document. Hybridan LLP and/or connected persons may, from time to time, have positions in, make a market in and/or effect transactions in any investment or related investment mentioned herein and may provide financial services to the issuers of such investments.
In the United Kingdom, this document is directed at and is for distribution only to persons who (i) fall within article 19(5) (persons who have professional experience in matters relating to investments) or article 49(2) (a) to (d) (high net worth companies, unincorporated associations, etc.) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (SI 2005/1529) (as amended) or (ii) persons who are each a professional client or eligible counterparty (as those terms are defined in the Financial Conduct Authority’s Conduct of Business Sourcebook) of Hybridan LLP (all such persons referred to in (i) and (ii) together being referred to as relevant persons). This document must not be acted on or relied up on by persons who are not relevant persons. For the purposes of clarity, this document is not intended for and should not be relied upon by any person who would be classified as a retail client under the Financial Conduct Authority’s Conduct of Business Sourcebook.
Neither this document, nor any copy of part thereof may be distributed in any other jurisdictions where its distribution may be restricted by law and persons into whose possession this document comes should inform themselves about, and observe, any such restrictions. Distribution of this report in any such other jurisdictions may constitute a violation of territorial and/or extra-territorial securities laws, whether in the United Kingdom, the United States or any other jurisdiction in any part of the world.
Where possible this document is made available to all relevant recipients at the same time. Dissemination of research by Hybridan LLP is monitored to ensure that it is only provided to relevant persons. Research prepared by Hybridan LLP is not intended to be received and/or used by any person who is a retail client.
Hybridan LLP and/or its associated undertakings may from time-to-time provide investment advice or other services to, or solicit such business from, any of the companies referred to in this document. Accordingly, information may be available to Hybridan LLP that is not reflected in this material and Hybridan LLP may have acted upon or used the information prior to or immediately following its publication. In addition, Hybridan LLP, the members, officers and/or employees thereof and/or any connected persons may have an interest in the securities, warrants, futures, options, derivatives or other financial instrument of any of the companies referred to in this document and may from time-to-time add or dispose of such interests.
This document may not be copied, redistributed, resent, forwarded, disclosed or duplicated in any form or by any means, whether in whole or in part other than with the prior written consent of Hybridan LLP.
MIFID II status of Hybridan LLP research
The cost of production of our corporate research is met by retainers from our corporate broking clients. In addition, from time to time we issue further communications as market commentary (such as our daily newsletter, Small Cap Breakfast), which we consider to constitute a minor non-monetary benefit which is capable of enhancing the quality of service provided by Hybridan LLP and which is of a scale and nature which could not be judged to impair the duty of Hybridan LLP to act in the best interest of its client falling within article 24(7)(b) of the MIFID II Regulation.
Hybridan LLP is a limited liability partnership registered in England and Wales, registered number OC325178, and is authorised and regulated by the Financial Conduct Authority and is a member of the London Stock Exchange. Any reference to a partner in relation to Hybridan LLP is to a member of Hybridan LLP or an employee with equivalent standing and qualifications. A list of the members of Hybridan LLP is available for inspection at the registered office, 2 Jardine House, The Harrovian Business Village, Bessborough Road, Harrow, Middlesex HA1 3EX.
If you would like to unsubscribe, please email email@example.com with “unsubscribe me”.